Iowanews Headlines

DelveInsight’s “Open-angle Glaucoma Pipeline Insight 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Open-angle Glaucoma pipeline landscape. It covers the Open-angle Glaucoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Open-angle Glaucoma Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Open-angle Glaucoma Pipeline? Click here to explore the therapies and trials making headlines @ Open-angle Glaucoma Pipeline Outlook Report

Key Takeaways from the Open-angle Glaucoma Pipeline Report

• On 19 September 2025, IVIEW Therapeutics Inc. announced a study subjects included will be 18 to 65 years of age (inclusion) and are diagnosed with primary open-angle glaucoma (POAG) for 1 year or more. Only participants who provide informed consent prior to all screening procedures will be eligible for enrollment into the trial.
• On 19 September 2025, AbbVie conducted a Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants with Open-Angle Glaucoma or Ocular Hypertension.
• DelveInsight’s Open-angle Glaucoma Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Open-angle Glaucoma treatment.
• The leading Open-angle Glaucoma Companies such as Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS and others.
• Promising Open-angle Glaucoma Therapies such as Citicoline eye drops 2%, VVN539 Ophthalmic Solution 0.02%, XEN45 (Glaucoma Gel Stent), Travoprost, NCX 470 and others.

Want to know which companies are leading innovation in Open-angle Glaucoma? Dive into the full pipeline insights @ Open-angle Glaucoma Clinical Trials Assessment

The Open-angle Glaucoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Open-angle Glaucoma Pipeline Report also highlights the unmet needs with respect to the Open-angle Glaucoma.

Open-angle Glaucoma Overview

Open-angle glaucoma (OAG) is the most prevalent form of glaucoma, characterized by a gradual increase in intraocular pressure (IOP) that leads to optic nerve damage. Unlike other forms of glaucoma, the drainage angle in OAG remains open, but the trabecular meshwork through which fluid drains becomes partially blocked. This blockage causes a buildup of pressure inside the eye, which over time, damages the optic nerve fibers, resulting in vision loss. The disease is often asymptomatic in its early stages, which is why it is referred to as “the silent thief of sight.”

Open-angle Glaucoma Emerging Drugs Profile

• NCX 470: Nicox Ophthalmics

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog that is currently being developed by Nicox Ophthalmics. NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470’s dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

• BTQ-1902: Betaliq, Inc.

BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta blocker. Beta blockers are one of the most commonly prescribed classes of medicines to treat glaucoma. Beta blockers reduce Intraocular Pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Beta blockers are often prescribed in combination with other glaucoma medications. Currently, the drug is in Phase II stage of Clinical trial evaluation for the Open-Angle Glaucoma Treatment.

• TO-O-1001: Theratocular Biotek

TO-O-1001 (MG-O-1001) eye drops is a patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension. Its therapeutic potency is established through a dual-targeting mechanism, which in turn leads to relaxation of the cells of trabecular meshwork and the inner walls of Schlemm’s canal. The combined results are an increase of aqueous humor outflow, which is necessary to achieve the intraocular pressure lowering effect. Animal studies showed superior efficacy results in IOP-lowering. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of open-angle glaucoma or ocular hypertension.

If you’re tracking ongoing Open-angle Glaucoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Open-angle Glaucoma Treatment Drugs

The Open-angle Glaucoma Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Open-angle Glaucoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Open-angle Glaucoma Treatment.
• Open-angle Glaucoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Open-angle Glaucoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Open-angle Glaucoma market.

Open-angle Glaucoma Companies

Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS and others.

Open-angle Glaucoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Open-angle Glaucoma Products have been categorized under various Molecule types such as,

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Open-angle Glaucoma Pipeline Report covers it all – check it out now @ Open-angle Glaucoma Market Drivers and Barriers, and Future Perspectives

Scope of the Open-angle Glaucoma Pipeline Report

• Coverage- Global
• Open-angle Glaucoma Companies- Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS and others.
• Open-angle Glaucoma Therapies- Citicoline eye drops 2%, VVN539 Ophthalmic Solution 0.02%, XEN45 (Glaucoma Gel Stent), Travoprost, NCX 470 and others.
• Open-angle Glaucoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Open-angle Glaucoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Open-angle Glaucoma Treatment landscape in this detailed analysis @ Open-angle Glaucoma Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Open-Angle Glaucoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Open-Angle Glaucoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Open-Angle Glaucoma Collaboration Deals
9. Late Stage Products (Phase III)
10. NCX 470: Nicox Ophthalmics
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BTQ-1902: Betaliq, Inc.
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I/II)
16. TO-O-1001: Theratocular Biotek
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Product Name: Company Name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Open-Angle Glaucoma Key Companies
23. Open-Angle Glaucoma Key Products
24. Open-Angle Glaucoma- Unmet Needs
25. Open-Angle Glaucoma- Market Drivers and Barriers
26. Open-Angle Glaucoma- Future Perspectives and Conclusion
27. Open-Angle Glaucoma Analyst Views
28. Open-Angle Glaucoma Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight